The candidate, CAN-2409, has specifically been granted the designation for use alongside prodrug valacyclovir to improve overall survival in patients with pancreatic ductal adenocarcinoma (PDAC).
CAN-2409 will now benefit from the FDA’s fast-track process, which is designed to improve the efficiency of product development and accelerate the review of treatments for serious conditions.
Pancreatic cancer is associated with a poor prognosis and is the fourth leading cause of cancer-related death in the US, accounting for approximately 3.3% of all new cancer cases.
